1. Epinephrine is used as the first-line treatment for anaphylaxis, and the mechanism of benefit involves all four major component processes of anaphylaxis simultaneously. Which of the following most accurately maps all four pharmacological mechanisms by which epinephrine reverses anaphylaxis, and explains why a selective beta-2 agonist would be inadequate as monotherapy?

• A) Selective beta-2 agonists (albuterol/salbutamol) are inadequate for anaphylaxis monotherapy because they address only the bronchospasm component: beta-2-mediated bronchial smooth muscle relaxation (Gs-cAMP-MLCK inhibition + BKCa opening) reverses bronchoconstriction but provides no: (1) Alpha-1-mediated vasoconstriction to reverse distributive shock (anaphylaxis-mediated mast cell histamine and tryptase cause massive endothelial H1-receptor-mediated vasodilation and increased capillary permeability, producing the distributive shock picture; alpha-1 on peripheral arterioles counteracts this by Gq-IP3-MLCK-mediated vasoconstriction, restoring SVR and MAP); (2) Beta-1-mediated cardiac support (positive inotropy and chronotropy restoring cardiac output against the vasodilated state); (3) Alpha-1-mediated upper airway angioedema reduction (alpha-1 vasoconstriction of mucosal vessels in the larynx and upper airway reduces endothelial leakage and mucosal edema from histamine-induced vascular permeability, providing the only specific pharmacological treatment for laryngeal edema in anaphylaxis -- beta-2 agonists have NO alpha-1 mucosal vasoconstriction and cannot reduce angioedema); (4) Beta-2-mediated inhibition of further mast cell and basophil mediator release (beta-2 receptor activation on mast cells and basophils increases cAMP, which inhibits phospholipase C activation and calcium-triggered degranulation, reducing ongoing histamine, tryptase, and leukotriene release -- a mechanism shared by epinephrine but absent in exogenous catecholamines that only address post-degranulation effects); epinephrine uniquely provides all four mechanisms in a single molecule within seconds of IM injection.
• B) Selective beta-2 agonists are inadequate for anaphylaxis because they are not available in injectable form and cannot achieve the plasma concentrations needed to reverse systemic anaphylaxis; the pharmacological mechanisms of beta-2 agonists in the lungs are identical to epinephrine's mechanisms; if a parenteral form of albuterol existed, it would be pharmacologically equivalent to epinephrine for all components of anaphylaxis.
• C) Epinephrine reverses anaphylaxis through two mechanisms: alpha-1 vasoconstriction (reversing shock) and beta-2 bronchodilation (reversing bronchospasm); the cardiac (beta-1) and anti-angioedema components are minor and not clinically significant; the reason beta-2 agonists are inadequate is only because they lack the alpha-1 vasoconstriction for shock reversal; the mast cell degranulation inhibition claimed for epinephrine's beta-2 mechanism is a theoretical effect that does not occur at clinical plasma concentrations achieved with IM injection.
• D) Epinephrine reverses anaphylaxis primarily through antihistamine properties -- epinephrine competes with histamine for H1 receptor binding on vascular endothelium and bronchial smooth muscle; its high potency relative to histamine means epinephrine displaces histamine from H1 receptors, reversing all histamine-mediated components of anaphylaxis; the adrenergic receptor effects (alpha, beta) are secondary and less important than the H1 competitive antagonism; antihistamines (diphenhydramine) are therefore pharmacologically equivalent to epinephrine for anaphylaxis but act more slowly, which explains why they are used as second-line agents.

2. The hemodynamic signatures of epinephrine and norepinephrine differ in clinically important ways. Which of the following most accurately compares the effects of low-dose epinephrine versus therapeutic-dose norepinephrine on heart rate, blood pressure components, pulse pressure, cardiac output, and systemic vascular resistance?

• A) Low-dose epinephrine (0.02-0.05 mcg/kg/min): heart rate increases (beta-1 SA node chronotropy); systolic BP rises (increased CO from beta-1 inotropy); diastolic BP may fall (beta-2 vasodilation in skeletal muscle and splanchnic beds reduces SVR); pulse pressure widens (elevated systolic + low/normal diastolic); cardiac output increases substantially (beta-1 inotropy + chronotropy); SVR decreases from beta-2 vasodilation; the clinical hemodynamic picture resembles moderate septic shock physiology (high CO, low SVR, widened pulse pressure). Therapeutic-dose NE (0.1-0.5 mcg/kg/min): heart rate often decreases (baroreceptor reflex vagal response to rising BP overrides direct beta-1 chronotropy); systolic BP rises; diastolic BP rises substantially (alpha-1 vasoconstriction increases SVR and DBP); pulse pressure narrows or is unchanged (both SBP and DBP rise proportionally); cardiac output decreases or remains stable (increased afterload from alpha-1 vasoconstriction may offset beta-1 inotropy); SVR increases markedly (alpha-1 dominant with no significant beta-2 counter-vasodilation); the clinical hemodynamic picture is high-resistance, elevated MAP -- ideal for vasodilatory/distributive shock.
• B) Low-dose epinephrine and therapeutic-dose NE produce identical hemodynamic effects -- both primarily activate alpha-1 receptors producing vasoconstriction and both are the first-line vasopressors for septic shock; the hemodynamic distinction is purely quantitative (epinephrine is more potent mg-for-mg than NE) not qualitative; the different hemodynamic profiles attributed to each drug in textbooks are derived from studies using different absolute doses and do not reflect true pharmacodynamic differences.
• C) Low-dose epinephrine decreases heart rate because beta-1 effects are only present at high doses; at low doses only alpha-2 receptor activation occurs, producing presynaptic NE release inhibition that reduces cardiac sympathetic tone and heart rate; NE at any dose increases heart rate substantially because it lacks the alpha-2 autoreceptor inhibitory mechanism that epinephrine uses to limit NE release.
• D) Norepinephrine reduces cardiac output at all doses because its alpha-1 vasoconstriction always increases afterload more than its beta-1 inotropy can compensate; this invariable cardiac output reduction is the primary reason NE is inferior to epinephrine for all shock states; epinephrine is pharmacologically superior to NE for all indications because it increases cardiac output at all doses while also providing vasoconstriction at high doses; current guidelines recommending NE as first-line for septic shock over epinephrine are based on non-pharmacological (cost, availability) rather than pharmacodynamic considerations.

3. The SOAP II trial (De Backer et al., NEJM 2010) compared dopamine to norepinephrine as first-line vasopressor in shock. Which of the following most accurately summarizes the pharmacological basis for the trial findings and the receptor-level explanation for dopamine's inferior safety profile?

• A) The SOAP II trial (n=1679 patients in shock -- septic, cardiogenic, and hypovolemic) found that dopamine compared to norepinephrine was associated with significantly higher rates of arrhythmia (24.1% versus 12.4%) and higher 28-day mortality in the cardiogenic shock subgroup (P=0.03); the pharmacological explanation for dopamine's higher arrhythmia rate: dopamine at vasopressor doses (greater than 10 mcg/kg/min) activates beta-1 receptors with greater chronotropic potency relative to inotropic effect than NE; additionally, dopamine at intermediate doses (3-10 mcg/kg/min) releases NE from cardiac sympathetic terminals (indirect beta-1 effect), producing an unpredictable and variable additional catecholamine surge that NE infusion alone does not; the combination of direct and indirect beta-1 activation produces disproportionate sinus tachycardia and atrial fibrillation (AF is driven by increased atrial automaticity from beta-1 overactivation); the higher mortality in the cardiogenic shock subgroup reflects dopamine's tendency to increase heart rate (worsening myocardial oxygen demand in an already ischemic heart) and the less predictable hemodynamic profile compared to the targeted alpha-1 vasopressor + separate dobutamine inotrope strategy that NE enables.
• B) The SOAP II trial showed that dopamine and norepinephrine were equally effective as vasopressors with equivalent rates of ROSC, organ failure, and mortality; the trial found no pharmacological advantage for either agent and concluded that either could be used as first-line vasopressor based on clinician preference; the recommendation for NE over dopamine in current guidelines is therefore based on cost (dopamine is more expensive than NE) rather than any efficacy or safety pharmacological difference.
• C) The SOAP II trial arrhythmia finding is explained by dopamine's D2 receptor activation on cardiac conduction tissue -- D2 receptor activation on AV nodal cells produces Gi-mediated hyperpolarization (GIRK channel activation), prolonging AV nodal conduction time and producing supraventricular tachyarrhythmias via re-entrant mechanisms; NE does not activate D2 receptors and therefore does not produce the AV nodal conduction abnormalities that drive dopamine-associated AF; blocking D2 receptors with haloperidol (D2 antagonist) during dopamine infusion would theoretically prevent dopamine-associated arrhythmias.
• D) The SOAP II trial demonstrated that dopamine's dose-dependent beta-1 activation (including indirect NE release at intermediate doses) produces substantially higher arrhythmia rates than NE; NE's more selective alpha-1 dominant profile with less relative beta-1 activation is associated with lower arrhythmia risk; in the cardiogenic shock subgroup, the higher arrhythmia rate of dopamine translated to higher 28-day mortality; these findings led to guideline recommendations for NE as the preferred first-line vasopressor in all shock types with dopamine reserved for selected patients (bradycardia combined with hypotension, or when NE is unavailable).

4. Dobutamine is used in dobutamine stress echocardiography (DSE) for patients who cannot perform exercise stress testing. Which of the following most accurately explains the pharmacological basis of dobutamine stress echocardiography and identifies the adverse effects that require monitoring during the test?

• A) Dobutamine stress echocardiography exploits dobutamine's beta-1 receptor-mediated increase in myocardial oxygen demand to provoke ischemia in territories supplied by stenotic coronary arteries; by progressively increasing dobutamine from 5 to 40 mcg/kg/min, the test creates pharmacological stress on the myocardium equivalent to physical exercise; mechanism of ischemia induction: beta-1 activation increases heart rate (shortens diastole, reducing coronary filling time), increases contractility (Starling-law and PKA-mediated: increasing myocardial O2 demand), and increases systolic wall stress (Laplace: wall stress = pressure x radius / 2x wall thickness); in territories supplied by a stenotic coronary artery, coronary blood flow cannot increase proportionally to the increased O2 demand, producing subendocardial ischemia; ischemia manifests on echo as regional wall motion abnormalities (RWMA) -- the area supplied by the stenotic artery shows reduced thickening and excursion (hypokinesis) or no motion (akinesis) or paradoxical motion (dyskinesis) during the high-dose dobutamine phase; wall motion abnormalities are visualized in real-time by echocardiography; atropine may be added if the target heart rate (85% of maximum predicted = 0.85 x (220 - age)) is not achieved at maximum dobutamine dose; adverse effects requiring monitoring: severe hypertension (beta-1 inotropy plus potential alpha-1 activation at high doses), symptomatic arrhythmias (atrial and ventricular), angina, hypotension from excessive beta-2 vasodilation at high doses, and rarely ventricular fibrillation; contraindications: recent MI (within 1 week), unstable angina, severe hypertension (greater than 180/110 mmHg), aortic stenosis, and uncontrolled arrhythmias.
• B) Dobutamine stress echocardiography works through beta-2-mediated coronary vasoconstriction -- at high doses (40 mcg/kg/min), dobutamine activates beta-2 receptors on coronary arteries that paradoxically produce vasoconstriction (the coronary beta-2 response is opposite to peripheral beta-2 vasodilation); this coronary beta-2 vasoconstriction limits blood flow to ischemia-prone territories; the test identifies ischemia by showing wall motion abnormalities in territories where coronary beta-2 vasoconstriction exceeds autoregulatory capacity.
• C) Dobutamine stress echocardiography uses dobutamine's direct cytotoxic effect on ischemia-vulnerable cardiomyocytes -- at high doses, dobutamine causes ATP depletion in cardiomyocytes with marginal oxygen supply; the ATP-depleted cells reduce their contractile function (hibernating myocardium reveals itself); this mechanism is identical to pharmacological hibernation testing and is the basis for viability assessment in dobutamine stress protocols.
• D) The stress mechanism of dobutamine echocardiography is primarily through alpha-1 vasoconstriction increasing afterload -- by increasing SVR (via alpha-1 at high doses), dobutamine stress increases myocardial wall stress (Laplace) and oxygen demand without increasing heart rate; the test therefore identifies ischemia by creating an afterload stress rather than a rate-pressure product stress; this afterload mechanism distinguishes DSE from exercise stress testing (which primarily increases heart rate) and explains why DSE is specifically useful in patients with heart block who cannot increase heart rate adequately.

5. Fenoldopam is specifically indicated for hypertensive emergency with concurrent acute kidney injury. Which of the following most accurately explains the D1 receptor-mediated mechanisms that make fenoldopam specifically renoprotective compared to other IV antihypertensives, and identifies the specific contraindication unique to fenoldopam?

• A) Fenoldopam's renal D1 receptor activation: D1 receptors (Gs-coupled, adenylyl cyclase activation, increased cAMP, PKA activation) are expressed at two critical renal sites: (1) Renal vascular smooth muscle (afferent and efferent arterioles, interlobular arteries): D1 activation produces vasodilation, increasing renal cortical blood flow and glomerular filtration rate; in hypertensive emergency with renal ischemia (renal arterioles reflexly constricted from neurohormonal vasoconstriction), D1-mediated dilation specifically reverses this renal vasoconstriction while lowering systemic BP; other IV antihypertensives (nicardipine, labetalol, hydralazine) lower systemic BP but do not specifically target renal vasodilation; (2) Proximal renal tubular epithelial cells: D1 activation by PKA phosphorylates and inhibits the apical Na+/H+ exchanger (NHE3) and the basolateral Na+/K+-ATPase on proximal tubular cells, reducing sodium reabsorption and producing natriuresis and diuresis independently of vascular effects; this tubular natriuresis is pharmacologically distinct from loop diuretic action (furosemide blocks NKCC2 in the loop of Henle) and provides additional benefit in volume-overloaded hypertensive emergency; no active metabolites, no dose adjustment needed in renal failure, offset within 30 minutes on discontinuation. Specific contraindication: fenoldopam contains sodium metabisulfite as a pharmaceutical preservative; sodium metabisulfite can trigger severe allergic reactions including bronchospasm in sulfite-sensitive individuals, including patients with asthma (estimated 5-10% of asthmatics are sulfite-sensitive); fenoldopam is therefore relatively contraindicated in sulfite-sensitive asthma patients; additionally, fenoldopam increases intraocular pressure and is contraindicated or used with great caution in glaucoma.
• B) Fenoldopam is renoprotective by activating D2 receptors on the renal juxtaglomerular apparatus, inhibiting renin secretion; by reducing renin, fenoldopam lowers angiotensin II (which is the primary mediator of renal afferent arteriolar vasoconstriction in hypertensive emergency); the specific contraindication is QT prolongation -- fenoldopam blocks hERG channels at therapeutic concentrations, prolonging the QT interval; it is contraindicated in patients with baseline QTc greater than 450 ms.
• C) Fenoldopam is renoprotective through a dual mechanism: D1 agonism on renal tubular cells produces direct renal tubular cell cytoprotection by activating anti-apoptotic signaling pathways (D1-Gs-cAMP-CREB-BCL2 upregulation); this cell survival mechanism is independent of vascular effects; the unique contraindication is hyperkalemia -- fenoldopam's inhibition of the renal Na+/K+-ATPase prevents potassium secretion in the cortical collecting duct, causing potassium retention and potentially fatal hyperkalemia in patients with pre-existing CKD.
• D) Fenoldopam's specific contraindication compared to other IV antihypertensives is its absolute prohibition in patients with prior stroke -- D1 receptor activation in the cerebrovascular bed produces paradoxical cerebral vasoconstriction (the cerebrovascular D1 response is opposite to the renal D1 vasodilation); in patients with recent stroke, fenoldopam-induced cerebral vasoconstriction can extend the ischemic penumbra; all other IV antihypertensives are safe post-stroke; fenoldopam should never be used within 30 days of an ischemic stroke regardless of indication.

6. In cardiogenic shock, the combination of norepinephrine plus dobutamine is physiologically more rational than either agent alone or high-dose dopamine. Which of the following most accurately explains the complementary pharmacological rationale for the NE plus dobutamine combination at the receptor level?

• A) The NE plus dobutamine combination in cardiogenic shock is irrational -- NE's alpha-1 vasoconstriction increases afterload, which reduces stroke volume in a failing ventricle (Laplace: increased systolic wall stress from elevated SVR reduces the ability of the LV to shorten against resistance); dobutamine's beta-2 vasodilation partially counteracts NE's vasoconstriction; the two drugs therefore work against each other; the rational pharmacological approach is a single agent that provides both inotropy and vasopressor effects simultaneously, which is why epinephrine is the preferred single-agent therapy for cardiogenic shock.
• B) The pharmacological rationale for NE plus dobutamine in cardiogenic shock: (1) NE's alpha-1-mediated vasoconstriction addresses the critical problem of inadequate coronary perfusion pressure (MAP) in cardiogenic shock; coronary arteries fill during diastole and require adequate aortic diastolic pressure (MAP - LVEDP) as the coronary perfusion pressure gradient; in cardiogenic shock, MAP is critically low (often less than 65 mmHg), limiting coronary blood flow and perpetuating ischemia; NE raises aortic diastolic pressure via alpha-1 vasoconstriction, restoring coronary perfusion pressure and potentially improving myocardial oxygen delivery; (2) Dobutamine's net beta-1 dominant (with mild beta-2) profile provides the inotropic support that NE cannot: dobutamine increases contractility (Gs-cAMP-PKA-L-type Ca2+ channel phosphorylation + phospholamban phosphorylation) and stroke volume; dobutamine's mild beta-2 vasodilation REDUCES the elevated PCWP (filling pressure) and SVR in cardiogenic shock, decreasing LV afterload and making it easier for the impaired LV to eject -- this is mechanistically important because the elevated SVR in cardiogenic shock (compensatory neurohormonal vasoconstriction) is part of the vicious cycle; (3) The critical insight: NE raises coronary perfusion pressure (enabling myocardial recovery) while dobutamine augments cardiac output and reduces the excessive filling pressures and SVR; the two agents target different limbs of the cardiogenic shock physiology and are mechanistically complementary, not additive.
• C) NE plus dobutamine is preferred over high-dose dopamine in cardiogenic shock because dopamine at high doses (alpha-1 dominant) increases SVR and afterload, which in a failing LV reduces stroke volume by increasing wall stress; dopamine's pronounced chronotropic effect at high doses worsens myocardial oxygen demand in an already ischemic heart; dopamine also produces more arrhythmias than NE (SOAP II); NE provides more targeted alpha-1 vasoconstriction for coronary perfusion pressure with less relative beta-1 chronotropy than dopamine; dobutamine provides inotropic support; the NE-dobutamine combination achieves what high-dose dopamine alone attempts but with more predictable, titratable, and receptor-targeted hemodynamics and lower arrhythmia risk.
• D) NE plus dobutamine is preferred specifically because the two drugs competitively interact at the beta-1 receptor -- NE at high concentrations partially occupies beta-1 receptors, producing submaximal inotropic stimulation; dobutamine, being a more selective and higher-affinity beta-1 agonist than NE, displaces NE from beta-1 receptors, providing full beta-1 inotropic activation while NE retains its alpha-1 vasoconstriction; this receptor competition model explains why dobutamine plus NE provides more inotropy than NE alone at the same NE dose.

7. The pharmacological properties of epinephrine used in local anesthesia as an adjunct create important clinical safety considerations. Which of the following most accurately explains the mechanism and rationale for epinephrine as a local anesthetic adjunct, and identifies the anatomical locations where it is absolutely contraindicated?

• A) Epinephrine in local anesthetic solutions (concentration 1:100,000 to 1:200,000, equivalent to 10-5 mcg/mL) acts via alpha-1 receptor-mediated vasoconstriction of local blood vessels at the injection site; alpha-1 activation of perivascular smooth muscle constricts arterioles and venules, reducing blood flow through the injection site; benefits: (1) Slows systemic absorption of the local anesthetic from the injection depot, prolonging the duration of local anesthesia (by 50-100% depending on the anesthetic and site) and reducing peak plasma concentration of the local anesthetic (reducing the risk of systemic local anesthetic toxicity -- CNS excitation, cardiovascular toxicity); (2) Provides a bloodless surgical field (particularly useful in ENT and dental procedures); (3) Allows higher total doses of local anesthetic to be used safely (by reducing systemic absorption rate); absolute contraindications for epinephrine as local anesthetic adjunct: anatomical sites supplied by end arteries without collateral circulation, where alpha-1-mediated vasoconstriction can produce complete ischemia leading to tissue necrosis: (a) Digits (fingers and toes) -- digital arteries are end arteries; (b) Penis (penile artery) -- used for dorsal penile nerve block; (c) Pinna (external ear) -- auricular arteries; (d) Tip of the nose; (e) Nasal septum; these sites require plain local anesthetic solutions without epinephrine; the mnemonic is "3 Ps, 2 Ds" -- Penis, Pinna, and... (Prominent end-arteries).
• B) Epinephrine in local anesthesia acts via beta-2 receptor-mediated vasodilation of local capillaries -- beta-2 vasodilation paradoxically slows local anesthetic absorption because the vasodilated capillaries have reduced velocity flow (laminar flow physics: vasodilation reduces flow velocity at constant cardiac output); this reduced flow velocity slows drug transport from the injection depot; the contraindication for epinephrine in digits, penis, and pinna is based on their having exclusively beta-2 (not alpha-1) vascular innervation, making epinephrine a vasodilator in these territories that increases (not decreases) local anesthetic absorption.
• C) Epinephrine in local anesthetic solutions acts primarily through beta-1 receptor activation on local mast cells, inhibiting histamine release and reducing the inflammatory response that would otherwise accelerate local anesthetic metabolism by attracting neutrophils expressing local anesthetic-degrading esterases; the contraindication in digits and other end-arterial territories reflects the mast cell-stabilizing effect being particularly pronounced in these anatomically restricted tissues where histamine-mediated inflammation is necessary for tissue repair and its inhibition causes wound healing failure.
• D) Epinephrine as local anesthetic adjunct operates through a direct physical mechanism -- the vasoconstrictor creates a chemically isolated "depot" around the anesthetic molecules by forming tight junctions in capillary endothelium via alpha-1 signaling; the tighter endothelium prevents transcapillary drug diffusion; the contraindication in end-arterial territories reflects the absence of capillary beds (end-arterial territories are perfused only by arteries with no capillaries) making the epinephrine-induced tight junction mechanism ineffective and the local anesthetic depot unprotected.

8. The epinephrine dose used in cardiac arrest (1 mg IV every 3-5 minutes) is derived from historical animal data and differs greatly from anaphylaxis doses. Which of the following most accurately explains the pharmacological rationale for the specific mechanism of benefit of epinephrine during CPR and compares it to the mechanism in anaphylaxis?

• A) Epinephrine's mechanism in cardiac arrest differs fundamentally from its mechanism in anaphylaxis: in cardiac arrest, the heart is in fibrillation or asystole and is not generating effective contractions; the primary pharmacological goal is NOT to stimulate the arrested heart but to increase coronary perfusion pressure during chest compressions; during CPR, aortic diastolic pressure during the decompression phase of chest compressions is the main determinant of coronary blood flow; epinephrine's alpha-1-mediated peripheral vasoconstriction raises aortic diastolic pressure by constricting peripheral arterioles (increasing the pressure in the aorta during the compression cycle), increasing the gradient for coronary perfusion (coronary perfusion pressure = aortic diastolic pressure minus LVEDP); the increased coronary perfusion pressure during CPR is the mechanism by which epinephrine improves ROSC; beta-1 effects (inotropic, chronotropic) are of secondary importance during active fibrillation/asystole because the heart cannot respond to inotropic stimulation when it is fibrillating; beta-1 effects become relevant AFTER ROSC, when they support post-resuscitation cardiac function but may also cause post-ROSC tachycardia and increased myocardial oxygen demand; in anaphylaxis, by contrast, the heart is beating (alpha-1 vasoconstriction reverses distributive shock, beta-1 supports cardiac output, beta-2 reverses bronchoconstriction and reduces angioedema) -- all four receptor mechanisms are therapeutically relevant simultaneously; the dose difference reflects the primary mechanism: 1 mg IV (large bolus for rapid peripheral vasoconstriction during CPR) versus 0.3-0.5 mg IM (lower dose titrated to adrenergic effect in a circulating patient).
• B) Epinephrine's mechanism in cardiac arrest is identical to its mechanism in anaphylaxis -- both require beta-1 cardiac stimulation as the primary mechanism; in cardiac arrest, beta-1 stimulation converts ventricular fibrillation to a more organized rhythm by stabilizing the membrane potential; in anaphylaxis, beta-1 stimulation maintains cardiac output against the vasodilated state; the higher dose in cardiac arrest (1 mg versus 0.3 mg in anaphylaxis) simply reflects the need for greater receptor occupancy to stimulate a fibrillating heart compared to a normally beating heart.
• C) The 1 mg epinephrine dose in cardiac arrest is derived from the observation that alpha-1 receptor-mediated vasoconstriction increases coronary perfusion pressure during CPR; the beta-1 component is actively harmful during cardiac arrest (increased myocardial oxygen demand during ischemia, potential for worsening ventricular fibrillation by increasing myocardial irritability); researchers have proposed using pure alpha-1 agonists (phenylephrine) for cardiac arrest to eliminate the harmful beta-1 component while retaining the beneficial alpha-1 vasoconstriction; clinical trials of phenylephrine versus epinephrine in cardiac arrest have shown superior ROSC rates and neurological outcomes with phenylephrine, which is why phenylephrine is now recommended as the preferred vasopressor in the 2023 AHA CPR guidelines.
• D) Epinephrine in cardiac arrest works through a direct electrical mechanism on cardiac pacemaker cells -- the 1 mg dose of epinephrine activates beta-1 HCN4 channels (If channels) in the AV node, converting the AV node into the dominant pacemaker at a rate of 40-60 bpm; this AV junctional rhythm is the "escape" rhythm that epinephrine establishes; the alpha-1 vasoconstriction is a secondary benefit; in asystole, epinephrine is most effective (converting asystole to AV junctional rhythm); in VF, epinephrine has no direct effect on the fibrillating rhythm and only the alpha-1 vasoconstriction provides any benefit.